The final piece of the puzzle fell into place when the China Stroke Primary Prevention Trial (CSPPT) reported in 201546 a significant 25% reduction of stroke with folic acid versus placebo in hypertensive patients receiving the ACE inhibitor enalapril. The gene discussed is ACE; the disease is stroke disorder.